Tamara Rordorf
University Hospital of Zurich(CH)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Brain Metastases and Treatment
Most-Cited Works
- → Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck(2016)4,966 cited
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,087 cited
- → Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression(2018)786 cited
- → Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study(2022)450 cited
- → KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)(2018)134 cited
- → Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2019)131 cited
- → CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer(2018)94 cited
- → Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study(2017)80 cited
- → SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets(2021)74 cited
- → IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes(2019)57 cited